[Featured Stock] Infinite Healthcare Rises on Huron's US FDA Approval of Dementia Analysis Software

Infinite Healthcare is showing strong performance. This is interpreted as being influenced by the news that Huron, a medical artificial intelligence (AI) company, received premarket notification approval from the U.S. Food and Drug Administration (FDA) for its dementia analysis software.

As of 1:31 PM on the 17th, Infinite Healthcare is trading at 5,200 KRW, up 6.12% compared to the previous day.

According to industry sources, Huron received FDA premarket notification approval on the 13th for its dementia imaging analysis software (Veuron-Brain-pAb3). This product automatically quantifies the degree of beta-amyloid deposition from an individual's PET images, which can be used for early diagnosis of dementia and new drug development.

Among dementias, Alzheimer's disease, which accounts for 75%, is a condition where increased production and decreased clearance of beta-amyloid protein cause protein deposition leading to nerve cell destruction. PET brain imaging tests are widely used for diagnosis.

Meanwhile, Infinite Healthcare has signed a product sales contract for Huron’s FDA-approved Parkinsonism brain lesion visualization AI solution product, 'Veuron-Brain-mN1.'

This content was produced with the assistance of AI translation services.